報價延遲最少15分鐘:2025/08/25 12:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.88 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.09/0.79
|
|
企業價值
389.92M
|
| 資產負債 |
|
每股賬面淨值
3.00
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
37.21M
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/25 12:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS,is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe. |
